Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Will novel oral formulations change the management of inflammatory bowel disease?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mometasone furoate nasal spray for the treatment of asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lixisenatide for type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Serotonin 2A receptor antagonists for treatment of schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pain freedom after 2 hours should be the primary outcome in controlled trials treating migraine attacks

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Plasma Glucose Levels Increase During Spontaneous Attacks of Migraine With and Without Aura

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cerebrovascular effects of endothelin-1 investigated using high-resolution magnetic resonance imaging in healthy volunteers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Introduction: The development of sumatriptan, more than 20 years ago, added substantially to the characterization of 5-hydroxytryptamine (5-HT) receptors and their relevance to acute migraine therapy. Recently, 5-HT1F receptor agonists, with no vascular effects, have shown efficacy in the treatment of migraines. Areas covered: This evaluation reviews the recent advances in acute migraine therapy targeting the 5-HT receptor. Specifically, the authors review the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of 5-HT1F receptor agonists and new formulations of sumatriptan and dihydroergotamine (DHE). Expert opinion: Lasmiditan, a non-vascular acting 5-HT1F receptor agonist, is effective in migraine but causes central nervous system-related adverse events, which may considerably limit its clinical use. The efficacy of transdermal sumatriptan is too low for general use in migraine. Intranasal sumatriptan powder could be a step forward compared with oral sumatriptan, but comparative trials are needed. Orally inhaled DHE has a very quick systemic absorption but the onset of effect in migraine is relatively slow with a maximum effect after 2 h. In contrast, orally inhaled DHE results in a low incidence of recurrence. None of these reviewed treatments are likely to fulfill patients' expectations, and the advancement of acute migraine drugs should likely depend on different mechanisms from current 5-HT-related drugs.
OriginalsprogEngelsk
TidsskriftExpert Opinion on Investigational Drugs
Vol/bind23
Udgave nummer3
Sider (fra-til)375-385
Antal sider10
ISSN1354-3784
DOI
StatusUdgivet - mar. 2014

ID: 42437327